Group of RAR alpha

Several members of the nuclear receptor family are directly associated with human malignancies including breast cancer, prostate cancer and leukemia. The pathogenesis of each of these diseases is underpinned by the activities of a member of the superfamily; estrogen receptor-alpha (ER alpha) in breast cancer, androgen receptor (AR) in prostate cancer, and retinoic acid receptor alpha (RAR alpha) in acute promyelocytic leukemia (1). Retinoic acid receptors are important in the regulation of growth and differentiation of epithelial tissues, embryonic and central nervous system development and hematopoiesis (2). Retinoids mediate their effect by two classes of nuclear receptor proteins, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs), that each consists of three isotypes (α, β, and γ) encoded in separate genes (3). Upon dimerization with RXR, RARs can bind to specific enhancer sequences in the DNA, so-called retinoic acid response elements (RAREs), resulting in transcriptional activation of target genes in the presence of ligand (4). The retinoic acid receptor alpha gene is the target of chromosomal rearrangements in all cases of acute promyelocytic leukemia (APL). RAR alpha is a negative regulator of promyelocyte differentiation when not complexed with RA, and stimulates this differentiation when bound to RA (5).
This His tagged recombinant RAR alpha was expressed in a baculovirus system; His-tagged and GST tagged ligand binding domain of RAR alpha were expressed from E.coli system.

RAR alpha can be applied in in vitro transcription assays, DNA-protein and protein-protein interaction assays.
The purified recombinant protein is greater than 90% homogeneous based on SDS-PAGE analysis.
1 unit equals 1 nanogram of purified protein.
variable in different lots
1x dilution buffer A: 20 mM Tris-Cl (pH 8.0), 20% Glycerol, 100 mM KCl, 1 mM DTT and 0.2 mM EDTA
 
References:
1. Hart S.M. (2002) Biol. Res. 35, 295-3003
2. Kastner et al. (1995) Cell, 83, 859-869
3. Leid et al., (1992) Trends Biochem. Sci. 17, 427-433
4. Linney et al., (1992) Curr. Top. Dev. Biol. 27, 309-350
5. Piazza et al. (2002) Oncogene 20, 7216-7222